| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2021―Sep―30 |
Evaluation of four in silico biomarkers for drug-induced proarrhythmic risk: COVID-19 off-label therapies case study |
Elisa Passini, Xin Zhou, Cristian Trovato, Annie Delaunois, Jean-Pierre Valentin, Alfonso Bueno-Orovio, Blanca Rodriguez |
| 2 |
[GO] |
2021―Sep―30 |
Detecting immunotoxicity in vitro-clinically relevant studies in the COVID-19 era |
Shaheda Ahmed, Anne Dickinson |
| 3 |
[GO] |
2021―Sep―30 |
In vitro cardiac safety evaluation for repurposed COVID-19 drugs by using human iPS cell-derived cardiomyocyte with gelatin fiber scaffold |
Toshiki Saotome, Atsushi Baba, Eriko Kato, Shigeki Joko, Naoki Shimada, Yuka Matsuzaki, et al. (+4) Toshiaki Endo, Yuji Ikegaya, Yuko Sekino, Kohei Sawada |
| 4 |
[GO] |
2021―Sep―30 |
Applying CiPA paradigm for assessing proarrhythmia risk of Covid-19 current off-label used therapies |
Annie Delaunois, Simon Hebeisen, Vitalina Gryshkova, Isabel Lushbough, Elisa Passini, Cristian Trovato, et al. (+2) Blanca Rodriguez, Jean-Pierre Valentin |
| 5 |
[GO] |
2021―Sep―30 |
Improved screening of the cardiovascular safety of COVID-19 anti-viral compounds |
Helen Maddock, Josh Hurst, Adam Linekar, Rob Wallis, Jeremy Billson |
| 6 |
[GO] |
2021―Jun―26 |
Safety pharmacology during the COVID pandemic |
Michael K. Pugsley, Yevgeniya Koshman, Tessa de Korte, Simon Authier, Michael J. Curtis |
|
